Cailin Conner

DocwireNews

Managing hemophilia requires a delicate balance between preventing bleeding episodes and minimizing the financial burden associated with therapy. In recent years, a significant shift toward personalized treatment approaches has gained momentum, particularly in the realm of pharmacokinetic (PK)-guided dosing. This approach tailors treatment plans to the unique needs of each patient, optimizing outcomes while considering variables like clotting factor levels, bleeding history, and treatment costs.A study published in <a href="https://onlinelibrary.wiley.com/doi/10.1111/hae.14826" target="_blank" rel="noopener">Haemophilia</a> investigated clinical outcomes before and after PK-guided&nbsp;prophylaxis in patients with hemophilia in order to better understand its benefits in terms of bleeding rates, treatment consumption, and costs.Researchers employed a retrospective design and included a cohort of 132 patients who were divided into 2 categories: those undergoing PK assessment for switching to a different treatment product (switchers) and those aiming to optimize their current treatment regimen (nonswitchers). The study analyzed various parameters, including annual bleeding rates (ABRs), mean weekly treatment consumption, and annualized cost of prophylaxis.&nbsp;The researchers found that the most prevalent treatments both before and after the index date were octocog alfa, rurioctocog alfa pegol, and efmoroctocog alfa. Of the 132 patients included in the study, 56% were categorized as switchers and 44% were identified as nonswitchers. Most patients (78%) experienced a decrease in ABR postindex or maintained zero ABR during both the pre- and postindex time periods. This trend was consistent in both switchers (77%) and nonswitchers (79.3%).Additionally, the results suggested that nonswitchers experienced no significant alteration in the cost of therapy. Conversely, switchers faced an increased cost of therapy, primarily due to the higher price associated with extended half-life products. A subset analysis further highlighted that patients receiving rurioctocog alfa pegol and efmoroctocog alfa achieved mean ABR values &lt;1 after the index date, suggesting effective protection against bleeding episodes.&nbsp;In conclusion, the authors wrote, &ldquo;PK-guided prophylaxis has the potential to improve clinical outcomes without increase in cost of therapy for patients maintaining product and can aid in maintaining effective protection against bleeds in those switching product.&rdquo;

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

PK-Guided Prophylaxis Shows Promise in Hemophilia Management

Hemophilia

A study investigated clinical outcomes before and after pharmacokinetic (PK)-guided dosing for hemophilia. 

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe